SCHEMBL18565019

SCHEMBL18565019

Cn1c2ccccc2c2cc(N(c3ccccc3)c3ccc4ccccc4c3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 4/20 0.48
MAPT P10636 3/20 0.48
HSD17B10 Q99714 3/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GPR3 P46089 1/20 0.46
PABPC1 P11940 1/20 0.40
PER2 O15055 1/20 0.39
CRY1 Q16526 1/20 0.39
CRY2 Q49AN0 1/20 0.39
KIF11 P52732 1/20 0.37
NPY5R Q15761 1/20 0.36
TERT O14746 1/20 0.36
BACE1 P56817 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18565024 0.92 MAPT (0.43) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL18565020 0.92 MAPT (0.43) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL23660606 0.92 KDM4E (0.46) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL18565031 0.91 KDM4E (0.38) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL18564994 0.91 GPR3 (0.46) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL12559383 0.91 GPR3 (0.55) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL12249804 0.91 GPR3 (0.55) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL29508672 0.89 MAPT (0.43) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL23660743 0.89 MAPT (0.43) KDM4EALDH1A1HPGDMAPTHSD17B10
SCHEMBL18565032 0.88 KDM4E (0.35) KDM4EALDH1A1HPGDMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10290815-B2 Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2019-05-14 US disclosed
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-03-02 US disclosed
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10290815-B2 Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device EED, BMI1, CD99 KDM4E 225/4885ALDH1A1 2977/4885HPGD 3304/4885
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE EED, BMI1, CD99 KDM4E 225/4885ALDH1A1 2977/4885HPGD 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.